Dr Barbara Mintzes

BA, MSc, PhD
Senior Lecturer, Faculty of Pharmacy
Member, Bias and Research Integrity Node, Charles Perkins Centre

Member of the Charles Perkins Centre

D17 - Charles Perkins Centre
The University of Sydney

Telephone +61 2 8627 0827
Fax +61 2 9351 4391

Biographical details

Dr Barbara Mintzes is a research scientist specialising in the study of pharmaceutical policy. Her research focuses on the effects of direct-to-consumer advertising of prescription drugs and other forms of pharmaceutical promotion on the prescribing and use of medicines. She also performs systematic reviews of clinical trial evidence regarding the health effects of medicines, including both benefit and harm, in terms of outcomes of importance to patients’ health. Dr Mintzes has
has a doctorate in Health Care and Epidemiology and was Associate Professor at the School of Population and Public Health at the University of British Columbia (UBC), Canada prior to joining the University of Sydney in April 2015. At UBC, she worked with the Therapeutics Initiative, a research group that evaluates new drugs as a background to provincial reimbursement decisions and produces an educational bulletin on drug treatments. Currently, she is the lead investigator on an international comparative study examining the influence of national regulations on the amount of safety information that pharmaceutical sales representatives provide to primary care physicians. Dr Mintzes was a lead member of an international WHO and Health Action International (HAI) project that involved developing an educational manual on drug promotion, for pharmacy and medical students. This manual has been translated into Spanish, Russian and French, and incorporated into education curricula in a range of settings. Dr Mintzes maintains strong community engagement, having worked for many years with women’s health and consumer groups, including DES (diethylstilbestrol) Action Canada, and Women and Health Protection (a Canadian non-profit organization). She co-authored the book “Sex, Lies and Pharmaceuticals” with Ray Moynihan, published in 2010.

Research interests

Dr Mintzes’ research focuses primarily on quality use of medicines, through studies that build the scientific evidence to support appropriate prescribing and use of medicines, and through evaluations of the effectiveness of policies aiming to support quality medicine use.

In the field of pharmaceutical policy, she has conducted research on pharmaceutical promotion, comparing the content of promotional information provided to consumers and physicians with the scientific evidence, and comparing national approaches to regulation and regulatory standards with promotional content. Her second related interest is the study of ‘disease-mongering’, i.e. commercial influences on diagnostic criteria and on the thresholds for treatment of specific conditions.

Current research projects include: a comparative evaluation of regulatory safety advisories on medicines in four countries over a 10-year period; an evaluation of antidepressant use in pregnancy in British Columbia; a systematic review of the beneficial and harmful effects of postpartum domperidone use to stimulate lactation; a systematic review of disease-awareness advertising; and an evaluation of the strength of evidence supporting recommendations for ‘off-label’ use of pharmaceuticals in a prescribing guide.

With the Charles Perkins Centre, Dr Mintzes’ research will evaluate how diagnostic thresholds and treatment outcomes are assessed in obesity, diabetes and cardiovascular disease, and particularly the influence of commercial interests. A second focus is the study of medications with cardiovascular and metabolic adverse events.

Teaching and supervision

Dr Mintzes has taught courses in critical appraisal and systematic review methods at the postgraduate level, and has been a faculty member for Cochrane Collaboration author training workshops, working with the Cochrane Hypertension Review Group. Another teaching area is on the influence of pharmaceutical promotion and ethics of interactions between health professionals and the industry. She has also been involved in a range of continuing professional education workshops for physicians and pharmacists on specific drugs and therapeutic areas, including contraceptives, anti-muscarinic drugs for overactive bladder, bisphosphonates, cholinesterase inhibitors, antidepressants and influenza drugs.

Current graduate student supervision

Janet Currie, PhD student, Interdisciplinary Studies. University of British Columbia Determinants of off-label medication use. Sept 2014 – ongoing [primary supervisor]

Suzie Maginley. MSc student, School of Population and Public Health.University of British Columbia. Social and economic determinants of potentially inappropriate prescribing behaviours. Sept 2014 – ongoing. [committee member]

Teresa Alves, PhD student. Department of Pharmaco-epidemiology & Clinical Pharmacy, Utrecht University. Disease-awareness advertising campaigns. Nov 2010 – ongoing [committee member]

2015 Summer Scholarship Project

Current research students

Project title Research student
International comparison of risk communication using regulatory drug safety advisories: policy and perceptions. Alice BHASALE
Medicines Safety Risk Communication: A Comparative Analysis of Content and Discordancy in Safety Advisories released by Australia, Canada, the United States and the European Union Lucy PERRY

Associations

Academic editor, PLoS ONE
Executive member, Therapeutics Initiative, Canada
Advisory board member, La Revue Prescrire, France
Board Member, Health Action International (HAI-Europe)
Member, International Society of Pharmacoepidemiology
Member, Canadian Association of Health Service and Policy Research
Affiliate Associate Professor, School of Population and Public Health, University of British Columbia
Steering Group Member, Women and Health Protection (Canada)
Member, Pharmaceutical Policy Research Collaboration (PPRC), Canada

Awards and honours

Michael Smith Health Research Foundation, Scholar Award 2008 – 2014
Prix Prescrire, for “Understanding and Responding to Pharmaceutical Promotion, A Practical Guide”, October 2013
Canadian Institutes of Health Research (CIHR) Post-doctoral Fellowship; 07/2003 – 06/2006

Keywords

drug promotion; pharmaceutical policy; Quality use of medicines ; medication safety; direct-to-consumer advertising

Selected grants

2017

  • How best to protect public health: a comparative analysis of regulatory safety warnings on medicines in Australia, Canada the European Union and the United States; Mintzes B, Roughead E, Lexchin J, Bero L, Dormuth C, Kesselheim A, Lipworth W, De Bruin M, Gnjidic D, Puil L; National Health and Medical Research Council (NHMRC)/Project Grants.

2016

  • Finding peace of mind: Navigating the marketplace of mental health apps; Grundy Q, Bero L, Jureidini J, Mintzes B, Raven M, Gillies D; Australian Communications Consumer Action Network/Research support.

2012

  • Pharmaceutical Sales Representatives and Patient Safety: exploration of physician experiences in three countries and implications for regulatory policy; Mintzes B, Lexchin J, Barer M, Bassett K, Sutherland J, Wiktorowicz M, Durrieu G, Morgan S, Tejani A, Wilkes M, Wright J; Canadian Institutes of Health Research/Research Support.
  • Psychotropic drug use in pregnancy: patterns of use and neonatal and infant health outcomes; Mintzes B, Wright J, Bassett K, Dormuth C, Oberlander T, Hanley G, Morgan S, Law M; Canadian Institutes of Health Research/Research Support.

2011

  • Pharmaceutical Sales Representatives & Patient Safety: Implications for Policy and Practice; Mintzes B; Canadian Institutes of Health Research/Research Support.
  • Clinical Evidence Reviews; Mintzes B, Perry T, Virani A, Fortin P; Ministry of Health, British Columbia/Research Support.
  • Maternal socioeconomic status, prenatal mental health and psychotroic medication use: associations with infant health.; Oberlander T, Janssen P, Mintzes B; Canadian Institutes of Health Research/Research Support.
  • Drug safety and effectiveness in Canada and abroad; Lexchin J, Wiktorowicz M, Mintzes B; Health Council of Canada/Research Support.

2010

  • Exposures to and outcomes of prescription drug use during pregnancy: population-based data linkage and analysis; Morgan S, Hanley G, Mintzes B; Canadian Institutes of Health Research/Research Support.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Mintzes, B. (2010). L' experience internationale du DES. In A. Levadou, M. Tournaire (Eds.), DES (Distilbène-Stilboestrol) : Trois générations : réalités - perspectives, (pp. 21-46). Paris: Vigot-Maloine.
  • Mintzes, B. (2009). "Ask your doctor" Women and direct-to-consumer advertising. In A. Ford, D. Saibil (Eds.), The Push to Prescribe, (pp. 17-46). Toronto: Canadian Women's Press.
  • Mintzes, B. (2009). Promotion of medicines and patient health. In B. Mintzes, D. Mangin, L. Hayes (Eds.), Understanding and Responding to Pharmaceutical Promotion: A Practical Guide, (pp. 9-24). Amsterdam: World Health Organization.
  • Mintzes, B., Toop, L., Mangin, D. (2009). Promotion to Consumers: Responding to patient requests for advertised medicines. In B. Mintzes, D. Mangin, L. Hayes (Eds.), Understanding and Responding to Pharmaceutical Promotion: A Practical Guide, (pp. 81-104). Amsterdam: World Health Organization.

Journals

  • Fabbri, A., Grundy, Q., Mintzes, B., Swandari, S., Moynihan, R., Walkom, E., Bero, L. (2017). A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. BMJ Open, 7(6). [More Information]
  • Parker, L., Karliychuk, T., Gillies, D., Mintzes, B., Raven, M., Grundy, Q. (2017). A health app developer's guide to law and policy: A multi-sector policy analysis. BMC Medical Informatics and Decision Making, 17(1), 1-13. [More Information]
  • Scheffer, P., Guy-Coichard, C., Outh-Gauer, D., Calet-Froissart, Z., Boursier, M., Mintzes, B., Borde, J. (2017). Conflict of Interest Policies at French Medical Schools: Starting from the Bottom. PloS One, 12(1). [More Information]
  • Lundh, A., Lexchin, J., Mintzes, B., Schroll, J., Bero, L. (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 2. [More Information]
  • Mintzes, B. (2017). Mental health care and suicide in pregnancy and postpartum. CMAJ, 189(48), E1498. [More Information]
  • Smolina, K., Morgan, S., Mintzes, B., Hanley, G., Oberlander, T. (2017). Response to �use of domperidone and risk of ventricular arrhythmia in the postpartum period: Getting to the heart of the matter�. Pharmacoepidemiology and Drug Safety, 26(7), 865-866. [More Information]
  • Leonardo Alves, T., Mantel-Teeuwisse, A., Paschke, A., Leufkens, H., Puil, L., Poplavska, E., Mintzes, B. (2017). Unbranded advertising of prescription medicines to the public by pharmaceutical companies. Cochrane Database of Systematic Reviews, 2017 (7). [More Information]
  • Habibi, R., Lexchin, J., Mintzes, B., Holbrook, A. (2017). Unwarranted claims of drug efficacy in pharmaceutical sales visits: Are drugs approved on the basis of surrogate outcomes promoted appropriately? British Journal of Clinical Pharmacology, 83(11), 2549-2556. [More Information]
  • Morgan, S., Gagnon, M., Mintzes, B., Lexchin, J. (2016). A better prescription: Advice for a national strategy on pharmaceutical policy in Canada. Healthcare Policy, 12(1), 18-36.
  • Vitry, A., Mintzes, B., Lipworth, W. (2016). Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. Journal of Pharmaceutical Policy and Practice, 9(3), 1-6. [More Information]
  • Hanley, G., Mintzes, B. (2016). In Reply. Obstetrics and Gynecology, 128(2), 406-406. [More Information]
  • Smolina, K., Morgan, S., Hanley, G., Oberlander, T., Mintzes, B. (2016). Postpartum domperidone use in British Columbia: a retrospective cohort study. CMAJ Open, 4(1), E13-E19. [More Information]
  • Hanley, G., Smolina, K., Mintzes, B., Oberlander, T., Morgan, S. (2016). Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. Obstetrics and Gynecology, 127(3), 553-561. [More Information]
  • Habibi, R., Guenette, L., Lexchin, J., Reynolds, E., Wiktorowicz, M., Mintzes, B. (2016). Regulating information or allowing deception? Pharmaceutical sales visits in Canada, France and the United States. Journal of Law, Medicine and Ethics, 44(4), 602-613. [More Information]
  • Morgan, S., Weymann, D., Pratt, B., Smolina, K., Gladstone, E., Raymond, C., Mintzes, B. (2016). Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age and Ageing, 45(4), 535-542. [More Information]
  • Smolina, K., Mintzes, B., Hanley, G., Oberlander, T., Morgan, S. (2016). The association between domperidone and ventricular arrhythmia in the postpartum period. Pharmacoepidemiology and Drug Safety, 25(10), 1210-1214. [More Information]
  • Grundy, Q., Fabbri, A., Mintzes, B., Swandari, S., Bero, L. (2016). The inclusion of nurses in pharmaceutical industry-sponsored events: Guess who is also coming to dinner? JAMA Internal Medicine, 176(11), 1718-1720. [More Information]
  • Mintzes, B. (2016). The tip of the iceberg of misleading online advertising: Comment on �Trouble spots in online direct-to-consumer prescription drug promotion: A content analysis of FDA warning letters�. International Journal of Health Policy and Management, 5(5), 329-331. [More Information]
  • Cosgrove, L., VAnnoy, S., Mintzes, B., Shaughnessy, A. (2016). Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. Accountability in Research, 23(5), 257-279. [More Information]
  • Jarvinen, T., Michaelsson, K., Jokihaara, J., Collins, G., Perry, T., Mintzes, B., Musini, V., Erviti, J., Gorricho, J., Wright, J., et al (2015). Authors' reply to lee and colleagues. BMJ, 351, 1-2. [More Information]
  • Mintzes, B., Lexchin, J., Quintano, A. (2015). Clinical trial transparency: Many gains but access to evidence for new medicines remains imperfect. British Medical Bulletin, 116(1), 43-53. [More Information]
  • Perry, T., Wright, J., Mintzes, B., O'Sullivan, C., Tejani, A. (2015). New oral anticoagulants. CMAJ, 187(8), 603-603. [More Information]
  • Jarvinen, T., Michaelsson, K., Jokihaara, J., Collins, G., Perry, T., Mintzes, B., Musini, V., Erviti, J., Gorricho, J., Wright, J., et al (2015). Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ, 350, 1-7. [More Information]
  • Smolina, K., Hanley, G., Mintzes, B., Oberlander, T., Morgan, S. (2015). Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study. PloS One, 10(5), 1-16. [More Information]
  • Mintzes, B. (2015). When drugs don't make it to market. BMJ, 350, 1-2.
  • Lexchin, J., Mintzes, B. (2014). A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation. International Journal of Risk and Safety in Medicine, 26(4), 213-225. [More Information]
  • Nguyen, C., MacEntee, M., Mintzes, B., Perry, T. (2014). Information for physicians and pharmacists about drugs that might cause dry mouth: A study of monographs and published literature. Drugs and Aging, 31(1), 55-65. [More Information]
  • Hanley, G., Mintzes, B. (2014). Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy and Childbirth, 14(1), 1-12. [More Information]
  • Herder, M., Gibson, E., Graham, J., Lexchin, J., Mintzes, B. (2014). Regulating prescription drugs for patient safety: Does Bill C-17 go far enough? CMAJ, 186(8), E287-E292. [More Information]
  • Mintzes, B. (2013). A leap of faith in antidepressant treatment? JAMA Psychiatry, 70(12), 1373-1373. [More Information]
  • Fortin, P., Mintzes, B., Innes, M. (2013). A Systematic Review of Intravitreal Bevacizumab for the Treatment of Diabetic Macular Edema. Canadian Agency for Drugs and Technologies in Health, 3(1), 12-19.
  • Mintzes, B., Smith, M. (2013). Evidence-based medicine: Strengths and limitations. Australian Prescriber, 36(S2), 17-21.
  • Mintzes, B. (2013). Medication safety: opening up the black box. BMJ Quality and Safety, 22(9), 702-704. [More Information]
  • Mintzes, B., Lexchin, J., Wilkes, M., Beaulieu, M., Reynolds, E., Sutherland, J., Durrieu, G. (2013). Pharmaceutical Sales Representatives and Patient Safety. Journal of General Internal Medicine, 28(11), 1395-1395. [More Information]
  • Mintzes, B., Lexchin, J., Sutherland, J., Beaulieu, M., Wilkes, M., Durrieu, G., Reynolds, E. (2013). Pharmaceutical sales representatives and patient safety: A comparative prospective study of information quality in Canada, France and the United States. Journal of General Internal Medicine, 28(10), 1368-1375. [More Information]
  • Shnier, A., Lexchin, J., Mintzes, B., Jutel, A., Holloway, K. (2013). Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools. PloS One, 8(7), 1-9. [More Information]
  • Mintzes, B. (2012). Advertising of Prescription-Only Medicines to the Public: Does Evidence of Benefit Counterbalance Harm? Annual Review of Public Health, 33, 259-277. [More Information]
  • Tejani, A., Siu, J., Wright, J., Bassett, K., Musini, V., Mintzes, B., Perry, T. (2012). Another hypertension visit. Canadian Family Physician - Le Medecin de Famille Canadien, 58(8), 829-830.
  • Vitry, A., Mintzes, B. (2012). Disease mongering and low testosterone in men: the tale of two regulatory failures. The Medical Journal of Australia, 196(10), 619-621. [More Information]
  • Siu, J., Tejani, A., Musini, V., Bassett, K., Mintzes, B., Wright, J. (2012). Hypertension control in patients with diabetes. Canadian Family Physician - Le Medecin de Famille Canadien, 58(1), 31-33.
  • Mintzes, B. (2012). New UK guidance on industry-health professional collaboration. BMJ, 344, 1-2. [More Information]
  • Daw, J., Mintzes, B., Law, M., Hanley, G., Morgan, S. (2012). Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001-2006). Clinical Therapeutics, 34(1), 239-249. [More Information]
  • Musini, V., Mintzes, B., Tejani, A., Wright, J. (2012). Review overemphasises benefits and downplays serious harms. BMJ, 345(7874, 14 September 2012), 1-1.
  • Mintzes, B., Abi-Jaoude, E., Ford, A. (2011). Antidepressants and pregnancy. CMAJ, 183(5), 585-585. [More Information]
  • Mintzes, B. (2011). Is patient information on prescribed drugs just another form of advertising? BMJ, 343, 1-1.
  • Mangin, D., Healy, D., Mintzes, B. (2011). Paroxetine is associated with malformation during pregnancy. BMJ, 343(7819), 1-1.
  • Mintzes, B. (2011). Regulation of formula advertising in the Philippines and promotion and protection of breastfeeding: A commentary on Sobel, Iellamo, Raya, Padilla, Olive and Nyunt-U. Social Science and Medicine, 73(10), 1449-1451. [More Information]
  • Law, M., Mintzes, B., Morgan, S. (2011). The sources and popularity of online drug information: An analysis of top search engine results and web page views. Annals of Pharmacotherapy, 45(3), 350-356. [More Information]
  • Mintzes, B., Fortin, P., Wright, J. (2010). Antidépresseurs et grossesse. Les inhibiteurs spécifiques de la recapture de la sérotonine. Medecine, 6(6), 255-257. [More Information]
  • Healy, D., Mangin, D., Mintzes, B. (2010). Risky business. The Hastings Center Report, 40(4), 4-8.
  • Healy, D., Mangin, D., Mintzes, B. (2010). The ethics of randomized placebo controlled trials of antidepressants with pregnant women. International Journal of Risk and Safety in Medicine, 22(1), 7-16. [More Information]
  • Biron, P., Mintzes, B., Lexchin, J., Gagnon, M., Wright, J., Hofmann, A., Musini, V. (2009). Is the DioVantage® patient support program direct-to-consumer advertising? Canadian Journal of Clinical Pharmacology, 16(2), e285-e286.
  • Mintzes, B., Mangin, D. (2009). Opinion: Direct-to-consumer advertising of prescription medicines: A counter argument. Future Medicinal Chemistry, 1(9), 1555-1560.
  • Mintzes, B. (2009). Should Canada allow direct-to-consumer advertising of prescription drugs?: No. Canadian Family Physician - Le Medecin de Famille Canadien, 55(2), 131-133.
  • Mintzes, B., Morgan, S., Wright, J. (2009). Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: A cautionary tale. PloS One, 4(5), 1-7. [More Information]

2017

  • Fabbri, A., Grundy, Q., Mintzes, B., Swandari, S., Moynihan, R., Walkom, E., Bero, L. (2017). A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. BMJ Open, 7(6). [More Information]
  • Parker, L., Karliychuk, T., Gillies, D., Mintzes, B., Raven, M., Grundy, Q. (2017). A health app developer's guide to law and policy: A multi-sector policy analysis. BMC Medical Informatics and Decision Making, 17(1), 1-13. [More Information]
  • Scheffer, P., Guy-Coichard, C., Outh-Gauer, D., Calet-Froissart, Z., Boursier, M., Mintzes, B., Borde, J. (2017). Conflict of Interest Policies at French Medical Schools: Starting from the Bottom. PloS One, 12(1). [More Information]
  • Lundh, A., Lexchin, J., Mintzes, B., Schroll, J., Bero, L. (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 2. [More Information]
  • Mintzes, B. (2017). Mental health care and suicide in pregnancy and postpartum. CMAJ, 189(48), E1498. [More Information]
  • Smolina, K., Morgan, S., Mintzes, B., Hanley, G., Oberlander, T. (2017). Response to �use of domperidone and risk of ventricular arrhythmia in the postpartum period: Getting to the heart of the matter�. Pharmacoepidemiology and Drug Safety, 26(7), 865-866. [More Information]
  • Leonardo Alves, T., Mantel-Teeuwisse, A., Paschke, A., Leufkens, H., Puil, L., Poplavska, E., Mintzes, B. (2017). Unbranded advertising of prescription medicines to the public by pharmaceutical companies. Cochrane Database of Systematic Reviews, 2017 (7). [More Information]
  • Habibi, R., Lexchin, J., Mintzes, B., Holbrook, A. (2017). Unwarranted claims of drug efficacy in pharmaceutical sales visits: Are drugs approved on the basis of surrogate outcomes promoted appropriately? British Journal of Clinical Pharmacology, 83(11), 2549-2556. [More Information]

2016

  • Morgan, S., Gagnon, M., Mintzes, B., Lexchin, J. (2016). A better prescription: Advice for a national strategy on pharmaceutical policy in Canada. Healthcare Policy, 12(1), 18-36.
  • Vitry, A., Mintzes, B., Lipworth, W. (2016). Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. Journal of Pharmaceutical Policy and Practice, 9(3), 1-6. [More Information]
  • Hanley, G., Mintzes, B. (2016). In Reply. Obstetrics and Gynecology, 128(2), 406-406. [More Information]
  • Smolina, K., Morgan, S., Hanley, G., Oberlander, T., Mintzes, B. (2016). Postpartum domperidone use in British Columbia: a retrospective cohort study. CMAJ Open, 4(1), E13-E19. [More Information]
  • Hanley, G., Smolina, K., Mintzes, B., Oberlander, T., Morgan, S. (2016). Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. Obstetrics and Gynecology, 127(3), 553-561. [More Information]
  • Habibi, R., Guenette, L., Lexchin, J., Reynolds, E., Wiktorowicz, M., Mintzes, B. (2016). Regulating information or allowing deception? Pharmaceutical sales visits in Canada, France and the United States. Journal of Law, Medicine and Ethics, 44(4), 602-613. [More Information]
  • Morgan, S., Weymann, D., Pratt, B., Smolina, K., Gladstone, E., Raymond, C., Mintzes, B. (2016). Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age and Ageing, 45(4), 535-542. [More Information]
  • Smolina, K., Mintzes, B., Hanley, G., Oberlander, T., Morgan, S. (2016). The association between domperidone and ventricular arrhythmia in the postpartum period. Pharmacoepidemiology and Drug Safety, 25(10), 1210-1214. [More Information]
  • Grundy, Q., Fabbri, A., Mintzes, B., Swandari, S., Bero, L. (2016). The inclusion of nurses in pharmaceutical industry-sponsored events: Guess who is also coming to dinner? JAMA Internal Medicine, 176(11), 1718-1720. [More Information]
  • Mintzes, B. (2016). The tip of the iceberg of misleading online advertising: Comment on �Trouble spots in online direct-to-consumer prescription drug promotion: A content analysis of FDA warning letters�. International Journal of Health Policy and Management, 5(5), 329-331. [More Information]
  • Cosgrove, L., VAnnoy, S., Mintzes, B., Shaughnessy, A. (2016). Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. Accountability in Research, 23(5), 257-279. [More Information]

2015

  • Jarvinen, T., Michaelsson, K., Jokihaara, J., Collins, G., Perry, T., Mintzes, B., Musini, V., Erviti, J., Gorricho, J., Wright, J., et al (2015). Authors' reply to lee and colleagues. BMJ, 351, 1-2. [More Information]
  • Mintzes, B., Lexchin, J., Quintano, A. (2015). Clinical trial transparency: Many gains but access to evidence for new medicines remains imperfect. British Medical Bulletin, 116(1), 43-53. [More Information]
  • Perry, T., Wright, J., Mintzes, B., O'Sullivan, C., Tejani, A. (2015). New oral anticoagulants. CMAJ, 187(8), 603-603. [More Information]
  • Jarvinen, T., Michaelsson, K., Jokihaara, J., Collins, G., Perry, T., Mintzes, B., Musini, V., Erviti, J., Gorricho, J., Wright, J., et al (2015). Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ, 350, 1-7. [More Information]
  • Smolina, K., Hanley, G., Mintzes, B., Oberlander, T., Morgan, S. (2015). Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study. PloS One, 10(5), 1-16. [More Information]
  • Mintzes, B. (2015). When drugs don't make it to market. BMJ, 350, 1-2.

2014

  • Lexchin, J., Mintzes, B. (2014). A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation. International Journal of Risk and Safety in Medicine, 26(4), 213-225. [More Information]
  • Nguyen, C., MacEntee, M., Mintzes, B., Perry, T. (2014). Information for physicians and pharmacists about drugs that might cause dry mouth: A study of monographs and published literature. Drugs and Aging, 31(1), 55-65. [More Information]
  • Hanley, G., Mintzes, B. (2014). Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy and Childbirth, 14(1), 1-12. [More Information]
  • Herder, M., Gibson, E., Graham, J., Lexchin, J., Mintzes, B. (2014). Regulating prescription drugs for patient safety: Does Bill C-17 go far enough? CMAJ, 186(8), E287-E292. [More Information]

2013

  • Mintzes, B. (2013). A leap of faith in antidepressant treatment? JAMA Psychiatry, 70(12), 1373-1373. [More Information]
  • Fortin, P., Mintzes, B., Innes, M. (2013). A Systematic Review of Intravitreal Bevacizumab for the Treatment of Diabetic Macular Edema. Canadian Agency for Drugs and Technologies in Health, 3(1), 12-19.
  • Mintzes, B., Smith, M. (2013). Evidence-based medicine: Strengths and limitations. Australian Prescriber, 36(S2), 17-21.
  • Mintzes, B. (2013). Medication safety: opening up the black box. BMJ Quality and Safety, 22(9), 702-704. [More Information]
  • Mintzes, B., Lexchin, J., Wilkes, M., Beaulieu, M., Reynolds, E., Sutherland, J., Durrieu, G. (2013). Pharmaceutical Sales Representatives and Patient Safety. Journal of General Internal Medicine, 28(11), 1395-1395. [More Information]
  • Mintzes, B., Lexchin, J., Sutherland, J., Beaulieu, M., Wilkes, M., Durrieu, G., Reynolds, E. (2013). Pharmaceutical sales representatives and patient safety: A comparative prospective study of information quality in Canada, France and the United States. Journal of General Internal Medicine, 28(10), 1368-1375. [More Information]
  • Shnier, A., Lexchin, J., Mintzes, B., Jutel, A., Holloway, K. (2013). Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools. PloS One, 8(7), 1-9. [More Information]

2012

  • Mintzes, B. (2012). Advertising of Prescription-Only Medicines to the Public: Does Evidence of Benefit Counterbalance Harm? Annual Review of Public Health, 33, 259-277. [More Information]
  • Tejani, A., Siu, J., Wright, J., Bassett, K., Musini, V., Mintzes, B., Perry, T. (2012). Another hypertension visit. Canadian Family Physician - Le Medecin de Famille Canadien, 58(8), 829-830.
  • Vitry, A., Mintzes, B. (2012). Disease mongering and low testosterone in men: the tale of two regulatory failures. The Medical Journal of Australia, 196(10), 619-621. [More Information]
  • Siu, J., Tejani, A., Musini, V., Bassett, K., Mintzes, B., Wright, J. (2012). Hypertension control in patients with diabetes. Canadian Family Physician - Le Medecin de Famille Canadien, 58(1), 31-33.
  • Mintzes, B. (2012). New UK guidance on industry-health professional collaboration. BMJ, 344, 1-2. [More Information]
  • Daw, J., Mintzes, B., Law, M., Hanley, G., Morgan, S. (2012). Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001-2006). Clinical Therapeutics, 34(1), 239-249. [More Information]
  • Musini, V., Mintzes, B., Tejani, A., Wright, J. (2012). Review overemphasises benefits and downplays serious harms. BMJ, 345(7874, 14 September 2012), 1-1.

2011

  • Mintzes, B., Abi-Jaoude, E., Ford, A. (2011). Antidepressants and pregnancy. CMAJ, 183(5), 585-585. [More Information]
  • Mintzes, B. (2011). Is patient information on prescribed drugs just another form of advertising? BMJ, 343, 1-1.
  • Mangin, D., Healy, D., Mintzes, B. (2011). Paroxetine is associated with malformation during pregnancy. BMJ, 343(7819), 1-1.
  • Mintzes, B. (2011). Regulation of formula advertising in the Philippines and promotion and protection of breastfeeding: A commentary on Sobel, Iellamo, Raya, Padilla, Olive and Nyunt-U. Social Science and Medicine, 73(10), 1449-1451. [More Information]
  • Law, M., Mintzes, B., Morgan, S. (2011). The sources and popularity of online drug information: An analysis of top search engine results and web page views. Annals of Pharmacotherapy, 45(3), 350-356. [More Information]

2010

  • Mintzes, B., Fortin, P., Wright, J. (2010). Antidépresseurs et grossesse. Les inhibiteurs spécifiques de la recapture de la sérotonine. Medecine, 6(6), 255-257. [More Information]
  • Mintzes, B. (2010). L' experience internationale du DES. In A. Levadou, M. Tournaire (Eds.), DES (Distilbène-Stilboestrol) : Trois générations : réalités - perspectives, (pp. 21-46). Paris: Vigot-Maloine.
  • Healy, D., Mangin, D., Mintzes, B. (2010). Risky business. The Hastings Center Report, 40(4), 4-8.
  • Healy, D., Mangin, D., Mintzes, B. (2010). The ethics of randomized placebo controlled trials of antidepressants with pregnant women. International Journal of Risk and Safety in Medicine, 22(1), 7-16. [More Information]

2009

  • Mintzes, B. (2009). "Ask your doctor" Women and direct-to-consumer advertising. In A. Ford, D. Saibil (Eds.), The Push to Prescribe, (pp. 17-46). Toronto: Canadian Women's Press.
  • Biron, P., Mintzes, B., Lexchin, J., Gagnon, M., Wright, J., Hofmann, A., Musini, V. (2009). Is the DioVantage® patient support program direct-to-consumer advertising? Canadian Journal of Clinical Pharmacology, 16(2), e285-e286.
  • Mintzes, B., Mangin, D. (2009). Opinion: Direct-to-consumer advertising of prescription medicines: A counter argument. Future Medicinal Chemistry, 1(9), 1555-1560.
  • Mintzes, B. (2009). Promotion of medicines and patient health. In B. Mintzes, D. Mangin, L. Hayes (Eds.), Understanding and Responding to Pharmaceutical Promotion: A Practical Guide, (pp. 9-24). Amsterdam: World Health Organization.
  • Mintzes, B., Toop, L., Mangin, D. (2009). Promotion to Consumers: Responding to patient requests for advertised medicines. In B. Mintzes, D. Mangin, L. Hayes (Eds.), Understanding and Responding to Pharmaceutical Promotion: A Practical Guide, (pp. 81-104). Amsterdam: World Health Organization.
  • Mintzes, B. (2009). Should Canada allow direct-to-consumer advertising of prescription drugs?: No. Canadian Family Physician - Le Medecin de Famille Canadien, 55(2), 131-133.
  • Mintzes, B., Morgan, S., Wright, J. (2009). Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: A cautionary tale. PloS One, 4(5), 1-7. [More Information]

For support on your academic profile contact .